# US 2020/0264184 A1 · Diagnostic, prognostic, and monitoring methods for solid tumor cancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0264184 A1
- Document ID: US20200264184A1
- Status: Published application
- Kind: A1
- Application number: 16/621,197
- Filed: 2018-06-13
- Published: 2020-08-20
- Earliest claimed: 2017-06-13
- Assignees: OncoTracker, Inc.
- Applicants: OncoTracker, Inc.
- Inventors: James Richard BERENSON
- Web page: https://patentgrep.com/patent/US20200264184A1

## CPC

- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- G01N 33/57585: {involving compounds identifiable in body fluids}
- G01N 33/57515: of the breast
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- G01N 2333/525: Tumor necrosis factor [TNF]
- G01N 2333/70578: NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The compositions and methods of the invention relate generally to detection of biomarkers for the diagnosis, prognosis, and monitoring of solid tumor cancers. In particular, the invention relates to compositions and methods for detection of B-cell maturation antigen (BCMA) for the diagnosis, prognosis, and monitoring of solid tumor type of cancers.

## Claims

### Claim 1

A method of prognosis for a solid tumor type of cancer in a subject, comprising detecting an amount of BCMA polypeptide or a fragment thereof in a biological sample obtained from the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the amount of BCMA polypeptide or a fragment thereof in the biological sample being lower than about 30 ng/mL correlates with a reduced time to progression (TTP) of the cancer.

### Claim 3 (depends on 1)

The method of claim 1, wherein the amount of BCMA polypeptide or a fragment thereof in the biological sample being lower than about 30 ng/mL indicates a reduced length of progression-free survival (PFS) for the subject.

### Claim 4 (depends on 1)

The method of claim 1, wherein the amount of BCMA polypeptide or a fragment thereof in the biological sample being lower than about 15 ng/mL or higher than about 150 ng/mL indicates a reduced OS for the subject.

### Claim 5

(canceled)

### Claim 6 (depends on 2)

The method of claim 2, wherein the biological sample is a serum sample.

### Claim 7

A method of monitoring progression or response to treatment of solid tumor cancer, comprising detecting an amount of BCMA or a fragment thereof in a biological sample obtained from a subject diagnosed with the cancer at a time point following treatment.

### Claim 8 (depends on 7)

The method of claim 7, wherein an amount of BCMA polypeptide or a fragment thereof in the biological sample of lower than about 30 ng/mL or higher than about 150 ng/mL indicates that the cancer will progress sooner.

### Claim 9 (depends on 7)

The method of claim 7, wherein an amount of BCMA polypeptide or a fragment thereof in the biological sample of higher than about 30 ng/mL but lower than about 150 ng/mL indicates that the cancer is more likely to enter remission or respond to treatment.

### Claim 10

(canceled)

### Claim 11 (depends on 7)

The method of claim 7, wherein the biological sample is a serum sample.

### Claim 12

(canceled)

### Claim 13 (depends on 7)

The method of claim 7, wherein the solid tumor cancer is breast cancer.

### Claim at position 14

14-15. (canceled)

### Claim 16

The method of any of the preceding claims, wherein the BCMA polypeptide or a fragment thereof is detected using a detection system selected from the group consisting of enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (MA), enzyme immunoassay (EIA), fluorescence immunoassay (FIA), luminescence immunoassay (LIA), lateral flow assay (LFA), and strip assay.

### Claim 17 (depends on 16)

The method of claim 16, wherein the detection system is a lateral flow assay.

### Claim 18 (depends on 16)

The method of claim 16, wherein the detection is performed using an antibody specific for BCMA polypeptide or a fragment thereof.

### Claim 19 (depends on 18)

The method of claim 18, wherein the antibody specific for BCMA polypeptide or a fragment thereof is a monoclonal antibody.

### Claim 20 (depends on 18)

The method of claim 18, wherein the antibody specific for BCMA polypeptide or a fragment thereof is a polyclonal antibody.

### Claim 21

A kit for monitoring progression or response to treatment of a solid tumor type of cancer in a subject, comprising a reagent suitable for determining levels of BCMA polypeptide or a fragment thereof in a biological sample obtained from the subject.

### Claim at position 21

22-25. (canceled)

### Claim 26

A method of treating breast cancer in a subject, comprising:
a) detecting an amount of BCMA polypeptide or a fragment thereof in a biological sample obtained from the subject; and
b) if the amount is greater than 15 ng/mL, administering an effective amount of letrozole, megestrol acetate, or letrozole and megestrol acetate.

### Claim 27 (depends on 26)

The method of claim 26, wherein the administering step is performed only if the amount is the amount is greater than 30 ng/mL.

### Claim 28 (depends on 26)

The method of claim 26, wherein the administering step is performed only if the amount is the amount is less than 150 ng/mL.

### Claim 29 (depends on 26)

The method of claim 26, wherein the biological sample is a serum sample.
